The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series.

McMillan A., O'Neill AT., Townsend W., Lambert J., Virchis A., Shah R., Menezes L., Humphries P., Von Both K., Grandage V., Carpenter B., Hough R., Ardeshna KM., Daw S.

DOI

10.1111/bjh.17274

Type

Journal article

Publication Date

2021-02-01T00:00:00+00:00

Volume

192

Pages

e84 - e87

Keywords

Bendamustine, Brentuximab, Hodgkin lymphoma, Refractory, Relapse, Salvage, Adolescent, Adult, Antineoplastic Agents, Alkylating, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Bendamustine Hydrochloride, Brentuximab Vedotin, Child, Female, Hodgkin Disease, Humans, Male, Neoplasm Recurrence, Local, Treatment Outcome, Young Adult

Permalink More information Close